Topics

Horizon Pharma’s Thyroid Eye Disease Treatment Could Become a Blockbuster, Analyst Predicts

20:00 EDT 28 Apr 2019 | BioSpace

Ireland-based Horizon Pharma reported additional statistically significant secondary data from its positive Phase III study at a conference and plans to continue to share analysis at future medical conferences.

Original Article: Horizon Pharma’s Thyroid Eye Disease Treatment Could Become a Blockbuster, Analyst Predicts

NEXT ARTICLE

More From BioPortfolio on "Horizon Pharma’s Thyroid Eye Disease Treatment Could Become a Blockbuster, Analyst Predicts"

Quick Search

Relevant Topic

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...